Proteome Regulatory News (PRM)

PRESS RELEASE

14 December 2015

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Director Dealing

Further to the announcement made earlier today regarding the purchase of Ordinary Shares in the Company by Vulpes Life Sciences Fund ("Vulpes"), the Company would like to announce that by virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 36,548,125 Ordinary Shares of the Company representing 16.03% of the issued share capital of the Company.

For further information please contact:

Notes to Editors:

About Proteome Sciences plc (www.proteomics.com)

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. The Company is headquartered in Cobham, UK, with laboratory facilities in London and Frankfurt.

Proteome Sciences' proprietary research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers in Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or have already been outlicensed.

The Company's PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to pharmaceutical, biotechnology and diagnostics companies from its ISO 9001: 2008 facility in Frankfurt, Germany.